Navigation Links
ReceptorBio Announces Diabetes License Agreement With Telik
Date:8/19/2008

FOSTER CITY, Calif., Aug. 19 /PRNewswire-FirstCall/ -- ReceptorBio, Inc. announced today that it has entered into a license agreement with Telik, Inc. (Palo Alto, CA) (Nasdaq: TELK) that would enable ReceptorBio to develop and commercialize Telik's unique, oral small molecule insulin receptor activators. These compounds were identified through the application of TRAP(R), Telik's proprietary drug discovery technology. The agreement provides for payments related to regulatory milestones and royalties based on product sales.

Pre-clinical testing has indicated that these insulin receptor activators, as single agents, lower glucose levels in models of diabetes. The compounds are active in the presence of sub-maximal levels of insulin, and do not cause hypoglycemia at the dose levels examined. This synergy with insulin suggests the compounds could potentially be co-administered with other anti-diabetic agents including insulin. The insulin receptor activating activity of these compounds suggests that they may be attractive drug candidates for advancing the treatment of Type 2 diabetes mellitus (T2D) and the Insulin Resistance/Metabolic Syndrome (Journal of Biological Chemistry (2002), 277, 43565-43571).

"ReceptorBio is very enthusiastic about gaining the opportunity to continue the development of the insulin receptor activator compounds discovered by Telik," said Joseph Evans, Ph.D., ReceptorBio's Co-founder and President. "These compounds have a unique mechanism of action directed against a validated drug target, the insulin receptor, and thus they represent a novel class of insulin sensitizers."

"The oral agents currently available on the market for the treatment of T2D are limited, and may be associated with undesirable
'/>"/>

SOURCE ReceptorBio, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
2. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
3. Arno Therapeutics Announces Second Quarter 2008 Financial Results
4. 4C Controls Announces the Appointment of Dr. Philip Hayden as Vice President, Security Assessment & Threat Analysis
5. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
6. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
7. Yongye Biotechnology International Announces Second Quarter Results
8. China Kangtai Cactus Biotech Announces Record Second Quarter Results
9. AMDL Inc. Announces Second Quarter 2008 Results; Company Posts $5.8 Million in Sales With a Revenue Increase of 140%
10. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
11. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Swedesboro, NJ (PRWEB) May 24, 2013 Dr. ... Elmer, NJ and Swedesboro, NJ, are proud to announce an ... event will take place on Saturday, June 8th from 10 ... Dr. Warmuth, Anamaria Newport, MHS, PA-C and staff will be ... dermal fillers, laser and aesthetic treatments, and provide complimentary cosmetic ...
(Date:5/24/2013)... May 24, 2013 In a ... industry suppliers will present technologies with applications in ... annual SPIE Optics and Photonics symposium ... SPIE, the international society for optics and ... multidisciplinary optical sciences and technology meeting in North ...
(Date:5/24/2013)... May 24, 2013 Bed bug cases tend ... themselves from the looming higher risk of becoming the pests' ... new bed bug guideline. In the guide, the company enumerated ... and avoiding them while traveling. , According to My ... increase of bed bug infestation during summer: the warm weather ...
(Date:5/24/2013)... Israel , May 24, 2013 ... leader in embolic protection stents, announced that Alan ... and Craig Shore , the Company,s Chief ... Investor Conference on Thursday May 30, 2013 at The Pfister ... The format of the conference includes a ...
Breaking Biology Technology:See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 2See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 3See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 4Steps for Getting Rid of Bed Bugs without Using Chemicals and Avoiding Them While Traveling Enumerated by My Cleaning Products in Its Latest Post 2Steps for Getting Rid of Bed Bugs without Using Chemicals and Avoiding Them While Traveling Enumerated by My Cleaning Products in Its Latest Post 3InspireMD To Participate In Benchmark Investor Conference On May 30th 2InspireMD To Participate In Benchmark Investor Conference On May 30th 3InspireMD To Participate In Benchmark Investor Conference On May 30th 4
... N.J., Feb. 5 Genta,Incorporated (Nasdaq: GNTA ) ... Dr. Raymond P. Warrell, Jr., will provide a,company overview ... &,Investor Conference. The presentation is scheduled for Wednesday, February,13th ... New York, NY., About Genta, Genta Incorporated ...
... LOUISVILLE, Colo., Feb. 5 Replidyne, Inc.,(Nasdaq: RDYN ) ... February 26, 2008 at 4:45 P.M. ET to report 2007 ... upcoming,investor conference in February 2008., Earnings conference call ... President and CEO, and other members of Replidyne,s ...
... Mass., Feb. 5 Echo Therapeutics,Inc. (OTC Bulletin ... announced today that Patrick T. Mooney, M.D, Chairman,and ... Small-Cap Investor,Conference on February 7, 2008 at 3:50 ... The conference will be held at the Four ...
Cached Biology Technology:Genta Incorporated to Present at the BIO CEO & Investor Conference 2Genta Incorporated to Present at the BIO CEO & Investor Conference 3Replidyne to Report 2007 Fourth Quarter and Year-End Earnings 2Replidyne to Report 2007 Fourth Quarter and Year-End Earnings 3Echo Therapeutics to Present at RedChip Small-Cap Investor Conference 2
(Date:5/23/2013)... Rollins School of Public Health at Emory University, ... Technology, have received a $4 million grant over ... Emory University (Health and Exposome Research Center: Understanding ... center grant awarded in the United States. ... National Institute of Environmental Health Sciences (NIEHS) of ...
(Date:5/23/2013)... the overall health, development, and academic success of ... ensuring that all students have opportunities to engage ... vigorous or moderate-intensity physical activity, says a new ... estimates suggest that only about half of school-age ... health and development. The report recommends that ...
(Date:5/23/2013)... cerebral palsy with autologous cord blood. Following a cardiac ... boy had been in a persistent vegetative state ... treatment with the cord blood containing stem cells, the ... learned to speak simple sentences and to move. "Our ... the long-held doubts about the effectiveness of the new ...
Breaking Biology News(10 mins):Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3Schools should provide opportunities for 60 minutes of daily physical activity to all students 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 3First successful treatment of pediatric cerebral palsy with autologous cord blood 2
... November 18, 2008 -- Researchers at the University of California, ... been used to block and reverse type 1 diabetes in ... the National Academy of Sciences , was led by Jeffrey ... an expert in the field of autoimmunity. "The findings ...
... at Birmingham (UAB) Center for Education and Research on ... to study the risks and benefits of a newer ... therapies that target the immune system of patients who ... disorders. The award will allow the UAB CERTs ...
... WEST LAFAYETTE, Ind. - Materials engineers have created a ... and, if perfected, might be used for environmental cleanup, ... would last longer than conventional filters for separating oil ... oil, traits that are usually mutually exclusive. Researchers attached ...
Cached Biology News:Musculoskeletal center wins $2.2 million for drug safety 2New filtering technology has environmental, industrial applications 2New filtering technology has environmental, industrial applications 3
... optically clear polystyrene formulation , High antibody-binding ... , Plates are certified for performance ... , Eight-well strips fit snugly in ... in use even if turned upside down ...
...
... an aqueous solution that contains a purified ... in a saline solution, pH 6.5 ... methylisothiazolone and 0.02% bromonitrodioxane as a preservative. ... and stabilizer for biologically active components in ...
... StabilGuard Biomolecule Stabilizer is a bovine protein-free ... is an aqueous solution that contains non-toxic ... saline), pH 6.6 - 7.2, and does ... maintains the activity of antibodies and other ...
Biology Products: